

REMARKS

The specification and the Abstract have been amended to correct an inadvertent error in formulae (1-1) and (1-2) for Z, wherein X in the formulae has been changed to X'. The basis for the change can be seen in the subsequent disclosure of X' at, e.g., page 7, line 1, and the overall disclosure at, e.g., page 6, line 18 to page 7, line 9 in the application.

Claims 45-61 correspond to original claims 1-32 and 44 amended to meet the limitations of the compounds of group VI defined in the Restriction Requirement issued October 4, 2001 in parent application 09/830,167.

Entry of the above amendment is respectfully requested.

Respectfully submitted,



Susan J. Mack
Registration No. 30,951

SUGHRUE MION, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860
Date: Jan. 4, 2002

APPENDIX


VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

Amend the specification by inserting before the first line of the sentence:

This is a Divisional of Application No. 09/830,167 filed April 23, 2001, the disclosure of which is incorporated herein by reference.

Page 6, the paragraph at lines 18-19 with formulas (1-1) and (1-5):



IN THE CLAIMS:


Please delete claims 1-44.

Please add new claims 45-61.


IN THE ABSTRACT OF DISCLOSURE:


The abstract is changed as follows:

Compounds expressed by the following general formula (1),



[wherein, R_{01} and R_{02} are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1) to (1-5)].





The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.